Phospho-PEA15 (S116) Antibody

What is PEA15 and what is the significance of its S116 phosphorylation site?

PEA15 (Phosphoprotein enriched in astrocytes, 15 kDa) is a small phosphoprotein that contains a death-effector domain (DED) and is abundantly expressed in astrocytes . It plays crucial roles in regulating mitogen-activated protein kinase pathways and apoptosis signaling .

The S116 site is one of two key phosphorylation sites (along with S104) on PEA15. Phosphorylation at S116 is primarily mediated by calcium/calmodulin-dependent protein kinase II (CaMKII) or AKT . This specific phosphorylation is significant because:

• It mediates conformational changes in the death-effector domain

• It alters binding specificity from ERK to FADD protein

• It contributes to protecting astrocytes from apoptosis

• It accelerates nuclear ERK1/2 translocation, which activates astroglial proliferation

Which kinases are responsible for phosphorylating PEA15 at the S116 position?

The phosphorylation of PEA15 at the S116 position is primarily regulated by two kinases:

• AKT (Protein Kinase B) - Preferentially phosphorylates the S116 site of PEA15

• CaMKII (Calcium/calmodulin-dependent protein kinase II) - Also targets the S116 position

This is in contrast to the S104 site, which is primarily phosphorylated by Protein Kinase C (PKC) . Research findings demonstrate that in experimental conditions with status epilepticus (SE), 3CAI (an AKT inhibitor) reduced PEA15-S116 phosphorylation in reactive CA1 astrocytes, while inhibitors of PKC (BIM), ERK1/2 (U0126), and CaMKII (KN-93) did not influence PEA15-S116 phosphorylation . This suggests that AKT may play the predominant role in maintaining PEA15-S116 phosphorylation in specific cellular contexts such as reactive astrogliosis.

What are the validated experimental applications for Phospho-PEA15 (S116) antibodies?

Phospho-PEA15 (S116) antibodies have been validated for several experimental applications, including:

• Western Blotting (WB): Typically used at dilutions of 1:500-1:2000

• Immunohistochemistry (IHC): Optimal dilutions range from 1:100-1:300

• ELISA: Recommended at dilutions around 1:5000

Most commercially available Phospho-PEA15 (S116) antibodies are raised in rabbits using synthetic peptides derived from human PEA-15 around the S116 phosphorylation site . These antibodies are typically cross-reactive with human, mouse, rat, and sometimes monkey PEA15 , making them versatile for comparative studies across different model systems.

What sample preparation techniques are critical for preserving PEA15 phosphorylation status?

Preserving phosphorylation status is crucial when working with phospho-specific antibodies like Phospho-PEA15 (S116). Key considerations include:

• Rapid sample processing: Phosphorylation states can change rapidly after cell lysis due to endogenous phosphatases

• Phosphatase inhibitors: Include cocktails containing sodium fluoride, sodium orthovanadate, and β-glycerophosphate in all buffers

• Cold temperature: Maintain samples at 4°C throughout processing

• Storage conditions: Upon receipt, store antibodies at -20°C or -80°C and avoid repeated freeze-thaw cycles

• Buffer composition: Use storage buffers containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide for antibody stability

For tissue samples specifically analyzed by immunohistochemistry, proper fixation timing is critical as overfixation may mask phosphoepitopes while underfixation may not preserve tissue architecture adequately.

How does S116 phosphorylation alter PEA15's binding partners and downstream signaling?

Molecular dynamics studies have revealed that phosphorylation of PEA15 at S116 creates significant allosteric changes that alter its binding preferences:

• Unphosphorylated PEA15: Preferentially binds to extracellular-regulated kinase (ERK)

• Doubly phosphorylated PEA15 (at both S104 and S116): Preferentially binds to Fas-associated death domain (FADD) protein

The molecular mechanism behind this switch involves:

• The binding interfaces between unphosphorylated PEA-15/ERK2 and phosphorylated PEA-15/FADD share a common scaffold including both the DED and C-terminal tail residues of PEA-15

• While unphosphorylated serine residues do not directly interact with ERK2, phosphorylated S116 engages in strong electrostatic interactions with arginine residues on FADD DED

• Upon PEA-15 binding, FADD repositions its death domain (DD) relative to the DED, an essential conformational change to allow the death-inducing signaling complex (DISC) assembly

This phosphorylation-mediated switch in binding partners explains how PEA15 can exert distinct and sometimes opposing cellular effects depending on its phosphorylation state.

How is PEA15 phosphorylation status linked to its dual role in tumor suppression versus promotion?

PEA15 has been identified as having both tumor-suppressor and tumor-promoter functions, with phosphorylation status appearing to be the critical determinant:

• Unphosphorylated PEA15: Functions primarily as a tumor suppressor

• Phosphorylated PEA15: Has been associated with tumor-promoting functions

Research suggests that the cellular environment crucially determines PEA-15 protein function by affecting its phosphorylation state . Specifically:

• High levels of unphosphorylated PEA-15 expression have been associated with good prognosis in ovarian cancer, neuroblastoma, and astrocytoma

• Conversely, PEA-15 is highly expressed in certain human glioblastomas and malignant pleural mesotheliomas, both aggressive malignancies with poor prognosis

Therefore, to properly evaluate PEA-15's role as a prognostic marker, it is necessary to assess not only its expression levels but also its phosphorylation status . This is particularly important in cancer types with known mutations in pathways that alter PEA-15 phosphorylation, including EGFR, Ras, or AKT .

How can researchers differentiate between the effects of S104 and S116 phosphorylation in experimental models?

Differentiating between the effects of S104 and S116 phosphorylation requires strategic experimental approaches:

• Phospho-specific antibodies: Use antibodies that specifically recognize PEA15 phosphorylated at S104 or S116

• Kinase inhibitors: Apply specific inhibitors of:

  • PKC (e.g., BIM) to block S104 phosphorylation

  • AKT (e.g., 3CAI) to block S116 phosphorylation

• Phosphomimetic mutants: Generate S104D/E or S116D/E mutations that mimic constitutive phosphorylation

• Phospho-null mutants: Create S104A or S116A mutations that prevent phosphorylation

Studies have demonstrated distinct roles for these phosphorylation sites. For example, in status epilepticus models:

• PEA15-S104 phosphorylation was upregulated in reactive CA1 astrocytes

• PEA15-S116 phosphorylation remained unaltered in CA1 astrocytes but was reduced in dentate astrocytes

When 3CAI (AKT inhibitor) was applied, it reduced PEA15-S116 phosphorylation in reactive CA1 astrocytes, while other inhibitors (BIM, U0126, KN-93) had no effect . This demonstrates that specific kinase inhibitors can be used to dissect the unique contributions of each phosphorylation site.

What controls should be included when validating Phospho-PEA15 (S116) antibody specificity?

To ensure proper validation of Phospho-PEA15 (S116) antibody specificity, researchers should include the following controls:

• Phosphatase treatment: Treating a portion of samples with lambda phosphatase to remove phosphate groups should eliminate signal from phospho-specific antibodies

• Blocking peptide competition: Using the immunizing phosphopeptide to compete with antibody binding

• Phospho-null mutants: Including samples expressing S116A mutant PEA15 that cannot be phosphorylated at this site

• Positive controls: Including samples known to have high levels of S116 phosphorylation (e.g., certain cell lines treated with growth factors that activate AKT)

• Cross-reactivity check: Testing against samples containing only S104-phosphorylated PEA15 to ensure no cross-reactivity

Most commercially available Phospho-PEA15 (S116) antibodies are affinity-purified from rabbit antiserum using epitope-specific immunogens , which should provide good specificity, but validation in each experimental system remains essential.

How is Phospho-PEA15 (S116) implicated in neurological conditions and astrocyte function?

Research indicates that PEA15 and its phosphorylation at S116 have significant implications for neurological conditions:

• Astrocyte survival: PEA15 is abundantly expressed in astrocytes and protects them from apoptosis, with S116 phosphorylation playing a key role in this protective effect

• Seizure models: In status epilepticus models, PEA15-S116 phosphorylation shows region-specific changes:

  • Remains unaltered in CA1 astrocytes

  • Is reduced in dentate astrocytes

• Reactive astrogliosis: Phosphorylated PEA15 accelerates nuclear ERK1/2 translocation, activating astroglial proliferation and upregulation of glial fibrillary acidic protein (GFAP), which are hallmarks of reactive astrogliosis

• AKT signaling: AKT-mediated phosphorylation of PEA15 at S116 appears to play a role in the maintenance of astrocyte function following seizures

These findings suggest that modulating PEA15 phosphorylation may represent a potential therapeutic approach for neurological conditions involving aberrant astrocyte function or survival.

What methodological advances are improving the study of PEA15 phosphorylation in complex tissues?

Recent methodological advances enhancing the study of PEA15 phosphorylation include:

• Molecular dynamics (MD) simulations: Allowing detailed examination of how phosphorylation allosterically mediates conformational changes of the DED and alters binding specificity

• Dual immunofluorescence: Enabling simultaneous detection of GFAP and phosphorylated PEA15 to specifically study astrocytic expression

• Regional analysis: Techniques allowing differentiation between distinct brain regions (e.g., CA1 vs. dentate gyrus) reveal region-specific changes in PEA15 phosphorylation

• Pharmacological approaches: Using specific kinase inhibitors (BIM, 3CAI, U0126, KN-93) to dissect the signaling pathways controlling PEA15 phosphorylation

• Quantitative image analysis: Advanced fluorescence intensity quantification methods provide precise measurement of phosphorylation levels in tissue sections

These approaches collectively enable more sophisticated analysis of PEA15 phosphorylation states in complex biological contexts, particularly in heterogeneous tissues like the brain.